By Business/Source
Currency:EUR
2025/Q3
Stock NameRevenueRatio
Product sales of GOHIBIC (vilobelimab)24K100.00%
By Country/Region
Currency:EUR
2024/FY
Stock NameRevenueRatio
United States165.79K100.00%